Calm the Noise

Semaglutide and tirzepatide can reduce hunger and make eating feel less mentally consuming. Here is what GLP-1/GIP physiology, clinical trials, titration, and the safety evidence tell us about how they work and what to expect.

What “food noise” really means

People often use the term “food noise” to describe a persistent or unwanted cognitive preoccupation with food. It might look like thinking about what to eat next while you are still eating, feeling pulled toward food cues, repeatedly negotiating with yourself about snacks, or continuing to think about food even when you are not physically hungry. This is different from perceived hunger, which usually asks how hungry your body feels at a particular moment. Hunger and food preoccupation can occur together, but they are not interchangeable. A person can feel physically hungry without being preoccupied with food, or think about food frequently even when physical hunger is low.

The term food noise is useful because many patients recognize the experience, but it is not yet a formal diagnosis or a universally validated clinical measurement. Most appetite studies measure related outcomes such as perceived hunger, fullness or satiety, cravings, desire to eat, control over eating, food-cue reactivity, food preferences, and measured calorie intake. These findings help us understand how medications may affect appetite signaling and eating behavior, but they do not directly prove that semaglutide or tirzepatide eliminates food noise in the same way for every patient. The most accurate conclusion is that these medications may reduce several experiences that can contribute to food noise, including hunger, cravings, food-cue reactivity, and the drive to eat.

The gut plays a key role in appetite regulation

After eating, intestinal cells release hormones that help coordinate digestion and energy balance. GLP-1 (glucagon-like peptide-1) is made largely by L cells in the intestine. GIP (glucose-dependent insulinotropic polypeptide) is released by K cells, especially in the upper small intestine, in response to nutrients such as fats and carbohydrates. Both hormones are known as incretins because they enhance insulin release when blood glucose is elevated. GLP-1 also suppresses glucagon when glucose is high, while GIP can support glucagon responses when glucose is low. [2]

GLP-1 influences eating through several interconnected pathways. In the pancreas, its glucose-dependent actions improve glucose handling. In the stomach and upper gut, it can slow gastric emptying, allowing nutrients to enter the intestine more gradually and potentially prolonging. At the same time, signals from gut receptors and vagal afferents, sensory nerve fibers carrying information from the gut to the brain, reach the brainstem and hypothalamic appetite-control pathways. GLP-1 receptors are also found in brain regions involved in satiety and food motivation. Together, these pathways help explain how GLP-1 can reduce not only physical fullness, but also the drive to eat.

Additionally, the brain story is more nuanced than “the injection crosses into the brain and switches off cravings.” Some circulating GLP-1 and medicines such as semaglutide can access brain regions with a relatively permeable blood-brain barrier, including the area postrema, which relays peripheral signals to appetite-regulating networks. Animal and human research supports effects on the central nervous system, but these mechanisms do not fully explain or reliably predict and individual’s weight loss. Much of the mechanistic evidence comes from animal. [2] [3]

Tirzepatide activates both GLP-1 and GIP receptors. GIP has distinct actions in pancreatic beta cells, adipose tissue, and energy-balance pathways. Preclinical work suggests that activating both receptors may complement GLP-1 effects on satiety and food intake, although the precise mechanisms underlying tirzepatide’s greater average weight loss when compared with selective GLP-1 agonists (like semaglutide) remain incompletely understood. Unlike GLP-1, GIP does not appear to meaningfully slow gastric emptying. Additionally, with long-acting GLP-1 based treatments, the effect on gastric emptying can diminish overtime, a phenomenon known as tachyphylaxis. [2] [3]

What human appetite studies actually show

Semaglutide’s appetite effects have been measured directly, although the early mechanistic study was small. In a randomized crossover trial, 30 adults with obesity received semaglutide dose-escalated to 1.0 mg or placebo for 12 weeks. During laboratory meals, semaglutide was associated with about 24% fewer calories consumed, less hunger and craving, better control of eating, and a lower preference for high-fat foods. Two participants withdrew because of gastrointestinal adverse events. This supports a link between less eating, hunger, and craving. However, it does not show that semaglutide treats intrusive thoughts or binge-eating disorder. [4]

A 2025 randomized phase 1 trial provides an early human look at tirzepatide. Among 114 overweight or obese adults without diabetes, participants receiving tirzepatide ate about 523 fewer calories than their own baseline intake at week 3 during an unrestricted lunch where they could eat as much as they wished. The placebo group increased its intake by about 11 calories from its own baseline, producing an estimated difference of about 534 calories between tirzepatide and placebo. Participants also reported lower appetite, cravings, perceived hunger, tendency to overeat, and reactivity to food in the environment. In functional MRI, tirzepatide reduced activation to some high-fat, high-sugar food images in several brain regions, but it did not significantly change the prespecified aggregate response to all highly palatable foods. The study was short, relatively small, and designed to explore mechanisms, not to predict a durable response for every person. [5]

The large pivotal trials answer a different question: what happens to body weight over time when these medicines are paired with lifestyle support? In STEP 1, 1,961 overweight or obese without diabetes received semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo. 86.4% versus 31.5% lost at least 5% of their body weight. Nausea and diarrhea were the most common adverse events, and 4.5% stopped semaglutide because of gastrointestinal events versus 0.8% with placebo. [6]

In SURMOUNT-1, 2,539 overweight or obese adults without diabetes received tirzepatide 5, 10, or 15 mg or placebo for 72 weeks, including a 20-week escalation period. Mean weight change was −15.0%, −19.5%, and −20.9% at 5, 10, and 15 mg, respectively, versus −3.1% with placebo. At least a 5% weight loss occurred in 85% to 91% of tirzepatide participants versus 35% with placebo. Gastrointestinal events were the most common and occurred mainly during dose escalation. Adverse events resulting in discontinuation ranged from 4.3% to 7.1% across tirzepatide doses versus 2.6% with placebo. [7]

These are impressive averages. STEP 1 and SURMOUNT-1 were separate trials, so their percentages should not be read as a head-to-head comparison. They also excluded people with diabetes in these pivotal populations, and trial participants were screened, monitored, and supported. The results do not mean a patient with diabetes, severe gastrointestinal disease, a history of an eating disorder, or multiple interacting medicines will have the same benefit or risk profile.

Why deliberate titration matters

The first dose of a GLP-1 program is deliberately not the “full effect” dose. FDA labeling starts Wegovy (semaglutide) at 0.25 mg once weekly for four weeks, then increases every four weeks through 0.5 mg, 1 mg, and 1.7 mg; maintenance for weight reduction is 1.7 or 2.4 mg, selected with response and tolerability in mind. If a patient does not tolerate an escalation step, the label allows delaying escalation. [8]

Zepbound (tirzepatide) starts at 2.5 mg once weekly for four weeks. It then increases to 5 mg, with further 2.5-mg increases only after at least four weeks on the current dose. Maintenance for weight reduction is 5, 10, or 15 mg, and the label explicitly says to select the dose according to response and tolerability; a lower maintenance dose can be used if a higher one is not tolerated. [9]

This is deliberate pacing. Nausea, vomiting, diarrhea, constipation, abdominal pain, and dyspepsia are common, particularly while the dose is rising. Gradual exposure gives the gastrointestinal tract and the patient time to adapt, while allowing the care team to distinguish a useful appetite change from intolerable illness. Because dosing is individualized, the pace of escalation should be based on response and tolerability. In many cases, a customized regimen or a slower increase can help reduce the chance of dehydration, inadequate nutrition, or an avoidable interruption in treatment.

What the medicines do not do

They do not remove the need for medical assessment, adequate nutrition, movement, sleep, or psychological care when those are relevant. They do not guarantee silence from food noise. While some people experience a marked reduction in food preoccupation, others may notice mainly earlier fullness, and some have little appetite effect or cannot tolerate treatment. A quieter mind is not the same as a cure for binge eating, an eating disorder, depression, trauma, or the social pressures that shape eating.

They also do not create a permanent reset after the last injection. In an exploratory, one-year extension of STEP 1, a representative subset regained 11.6 percentage points of body weight after semaglutide withdrawal, retaining a net 5.6% loss from baseline; the authors described this as roughly two-thirds of prior weight loss regained. In SURMOUNT-4, selected adults who had completed a 36-week tirzepatide lead-in lost another 5.5% when treatment continued but regained 14.0% after switching to placebo over the next 52 weeks. These withdrawal studies support obesity’s chronic biology and the need to discuss long-term maintenance to successfully keep weight off. [10] [11]

Finally, compounded medication can meet a real patient-specific need when an FDA-approved product is not appropriate or is not available in the needed formulation. A 503A pharmacy is a state-licensed pharmacy that compounds for an individual patient after receiving a prescription. A 503B outsourcing facility is a separate FDA-registered category that may compound larger batches under federal requirements. Both operate within regulatory and quality frameworks, and 503A pharmacies are also subject to state board of pharmacy oversight. PCAB accreditation is a separate quality program administered by the Accreditation Commission for Health Care. It evaluates pharmacy processes for sterile and/or nonsterile compounding. PCAB accreditation is a meaningful quality signal, but compounded medications are still not FDA-approved and do not undergo the same premarket review as FDA-approved products. [12] [13] [14]

What this means in practice

The following can be a helpful opening question: What changed in your thoughts about food, hunger, and eating, and what did not? Over time, it can be useful to ask how often food occupies the person’s thoughts, how intense cravings feel, how easily attention can shift, and whether food-related thoughts affect meals, work, sleep, or social life. These observations should be considered alongside physical hunger, fullness, actual calorie intake, and weight trend, because a reduction in food preoccupation does not necessarily mean that every aspect of appetite has changed.

The practical goal is not to chase a perfectly quiet mind. It is to understand whether food feels less mentally consuming in a way that supports eating patterns, daily life, and overall health. People may notice changes in food preoccupation before changes in body weight, or may experience less physical hunger without much change in food-related thoughts. Tracking both experiences over time can help the care team decide whether the treatment is providing a meaningful benefit for that individual.

Medical-education disclaimer: This article is for general education, not individualized medical advice. Do not start, stop, compound, reconstitute, or change a prescription based on this article. Decisions about semaglutide, tirzepatide, dosing, titration, and monitoring should be made with a qualified clinician who knows the patient’s medical history and the exact product being used.